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Abstract
Background: Anxiety is a serious personal health condition and represents a substantial burden to overall quality of life.
Additionally anxiety disorders represent a significant cost to the health care system as well as employers through benefits
coverage and days missed due to incapacity. This study sought to explore the effectiveness of naturopathic care on anxiety
symptoms using a randomized trial.
Methods: Employees with moderate to severe anxiety of longer than 6 weeks duration were randomized based on age and
gender to receive naturopathic care (NC) (n=41) or standardized psychotherapy intervention (PT) (n=40) over a period of
12 weeks. Blinding of investigators and participants during randomization and allocation was maintained. Participants in the
NC group received dietary counseling, deep breathing relaxation techniques, a standard multi-vitamin, and the herbal
medicine, ashwagandha (Withania somnifera) (300 mg b.i.d. standardized to 1.5% withanolides, prepared from root). The PT
intervention received psychotherapy, and matched deep breathing relaxation techniques, and placebo. The primary
outcome measure was the Beck Anxiety Inventory (BAI) and secondary outcome measures included the Short Form 36 (SF-
36), Fatigue Symptom Inventory (FSI), and Measure Yourself Medical Outcomes Profile (MY-MOP) to measure anxiety, mental
health, and quality of life respectively. Participants were blinded to the placebo-controlled intervention.
Results: Seventy-five participants (93%) were followed for 8 or more weeks on the trial. Final BAI scores decreased by 56.5%
(p,0.0001) in the NC group and 30.5% (p,0.0001) in the PT group. BAI group scores were significantly decreased in the NC
group compared to PT group (p=0.003). Significant differences between groups were also observed in mental health,
concentration, fatigue, social functioning, vitality, and overall quality of life with the NC group exhibiting greater clinical
benefit. No serious adverse reactions were observed in either group.
Relevance: Many patients seek alternatives and/or complementary care to conventional anxiety treatments. To date, no
study has evaluated the potential of a naturopathic treatment protocol to effectively treat anxiety. Knowledge of the
efficacy, safety or risk of natural health products, and naturopathic treatments is important for physicians and the public in
order to make informed decisions.
Interpretation: Both NC and PT led to significant improvements in patients’ anxiety. Group comparison demonstrated a
significant decrease in anxiety levels in the NC group over the PT group. Significant improvements in secondary quality of life
measures were also observed in the NC group as compared to PT. The whole system of naturopathic care for anxiety needs to
be investigated further includinga closerexamination of the individual components within the context of their additive effect.
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Introduction
Anxiety disorders are among the most prevalent type of
psychiatric disorder with an estimated lifetime incidence ranging
between 7.9% and 14.5% worldwide [1,2,3]. These disorders are
associated with considerable chronicity, morbidity, and disability
[3,4,5]. Anxiety has been associated with increased risk for other
disease conditions and plays an important role in overall quality of
life, as well as ability to function in normal daily living. In addition,
anxiety disorders impose high individual and social burden, tend
to be chronic, and can be as disabling as somatic disorders.
Compared with those who have other psychiatric disorders, people
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general practitioners more frequently than to psychiatric profes-
sionals, placing a strain upon the health care system and/or
private insurance drug benefit plans. The economic costs of
anxiety disorders include psychiatric, and nonpsychiatric emer-
gency care; hospitalization; prescription drugs; reduced produc-
tivity; absenteeism from work; and suicide [2].
Several studies have demonstrated the economic repercussions of
widespread anxiety in the workplace[2,3,6]. A data set from a large
employer database has demonstrated both the medical and
productivity costs of anxiety disorder [6]. This study concluded
that, employees diagnosed with anxiety disorders were significantly
more likely to have additional diagnoses, use more services, require
hospitalization, or visit the emergency room compared with the
control group based on analysis of work and medical records. In the
final analysis, after controlling for differences in comorbidities
employees diagnosed with anxiety disorders had significantly higher
medical costs, productivity costs, and total costs compared with the
control group [6]. Data from the World Health Organization
Collaborative Study on Psychological Problems in General Health
(WHO-PPGHC) reveals the impact of psychiatric illnesses and
comorbidities in terms of increased disability in a primary care
population [7]. This study reported the mean number of work loss
days with marked disability (during the past 30 days) due to any
anxiety disorder to be 19; higher than diabetes and heart disease.
Although complementary and alternative medicine (CAM)
treatments are popular in the general population [7] as well as
in those suffering from anxiety [8,9,10], there is limited or
sometimes contradictory evidence to support their use in the
treatment of anxiety disorders [8]. Previous CAM research on
anxiety has generally been focused on the effectiveness of a single
intervention or therapy [11,12], with no previous studies
investigating naturopathic approaches. At the same time, recent
trends in the treatment of anxiety reveal a significant superiority of
combination psychotherapy and pharmacological intervention
over monotherapy (either psychotherapy or pharmacological
treatment) [13]. This movement towards the use of multiple types
of treatment for anxiety in clinical practice not only reflects the
overall values and practice inherent to many CAM therapies
[14,15], but also presents many challenges to research using the
randomized trial design [16,17]. To address these concerns, CAM
research often employs a pragmatic randomized controlled trial
design; which is most useful to investigate whether an intervention
works under real-life conditions, as well as whether it is effective
for outcomes that matter to the patient [18].
Naturopathic medicine (also known as naturopathy) is a school
of medical philosophy and practice that seeks to improve health
and treat disease chiefly by assisting the body’s innate capacity to
recover from illness and injury. This alternative medical system of
care employs the use of many CAM therapies including
acupuncture, herbal medicine, osteopathy, nutrition, homeopathy,
and lifestyle counseling[19] in a combined manner to address the
underlying cause of disease. No previous studies have investigated
the impact of a naturopathic approach for anxiety.
Behavioral interventions such as diaphragmatic breathing have
been shown to reduce anxiety levels and improve coping capability
in stressful situations [20]. Therapies identifying negative stress
coping patterns and replacing them with positive outlets are
effective means of controlling and treating anxiety [21]. The
results of a large meta-analysis conducted by Faragher et al
indicates that stress reduction counseling is an effective primary
care treatment for widespread health concerns including mental
health, anxiety, self-esteem, physical health, and job satisfaction in
the workplace [22].
Withania somnifera, has been an important herb in use within the
Ayurvedic and indigenous medical systems for over 3000 years.
Clinical trials and animal research support the use of Withania
somnifera for anxiety, inflammation, Parkinson’s disease, cognitive
and neurological disorders and as a useful adjunct for patients
undergoing radiation and chemotherapy. Withania somnifera is also
used therapeutically as an adaptogen for patients with nervous
exhaustion, insomnia, debility due to stress, and as an immune
stimulant in patients with low white blood cell counts [23,24].
The major biochemical constituents of Withania somnifera root
are steroidal alkaloids and steroidal lactones in a class of
constituents called withanolides [23,24]. At present, 12 alkaloids,
35 withanolides, and several sitoindosides from this plant have
been isolated and studied. A sitoindoside is a withanolide
containing a glucose molecule at carbon 27. Much of Withania’s
pharmacological activity has been attributed to two main
withanolides, withaferin A and withanolide D [23,24].
Theoretically, the withanolides serve as important hormone
precursors which may be convertible into human physiologic
hormones as needed. Withania is thought to be amphoteric [23,24];
i.e. it can help regulate important physiologic processes. The
theory is that when there is an excess of a certain hormone, the
plant-based hormone precursor occupies cell membrane receptor
sites so the actual hormone cannot attach and exert its effect. If the
hormone level is low, the plant-based hormone exerts a small
effect. Withania may also facilitate the ability to withstand stressors,
and has antioxidant properties as well. Other studies have shown
Withania somnifera to have an immunostimulatory effect [25].
Most studies on Withania’s anxiolytic effect are based on animal
studies. In one study the anxiolytic and antidepressive actions of
Withania somnifera were compared to commonly prescribed
pharmaceuticals. In this preclinical work, an extract of the root
was administered orally to rats once daily for five days and results
were compared to a group administered the anxiolytic benzodi-
azepine lorazepam and the tricyclic antidepressant imipramine
[26]. Both the Withania group and the lorazepam group
demonstrated reduced brain levels of a marker for clinical anxiety.
Other preclinical studies confirm these results, lending support to
the use of Withania as an antistress adaptogen [25,27,28,29]. In a
recently published study we demonstrated the anxiolytic potential
of a compound natural health product which had Withania as the
main herb in an open label human trial [30].
A study showing the role of a Withania extract on central
nervous system calcium antagonism, sheds some light on a
potential anxiolytic mechanism of action. In this study by Grunze
et al, Withania extract supplementation resulted in extracellular
calcium antagonism in neurons thereby counteracting excitation
[31]. Calcium excitation has been shown to play a role in various
psychiatric conditions including anxiety, and it is reasonable to
expect an anxiolytic action when calcium excitation in inhibited.
Naturopathic treatment generally includes suggested alterations
in patients’ diet. Diets high in stimulants have been linked to
symptoms of anxiety. Reducing stimulants such as caffeine,
chocolate, nicotine, refined sugars will reduce incidence and
severity of anxiety [32]. Studies have shown that reduction in
dietary fat and alcohol also reduces the vulnerability to stress
responses [33,34].
Objective
We aimed to determine the effectiveness of naturopathic
interventions on anxiety symptoms and general health as
compared to a standardized psychotherapy intervention, utilizing
a randomized controlled pragmatic trial based on whole systems
research trial design [35].
Naturopathic Care for Anxiety
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Ethics Statement
This research was conducted according to the principles
expressed in the Declaration of Helsinki and received approval
and oversight from the research ethics board of The Canadian
College of Naturopathic Medicine and Health Canada’s Natural
Health Products Directorate Clinical Trial Division. Study
products were manufactured and dispensed to participants under
Good Manufacturing Practices and met Health Canada criteria
for quality[36]. All participants provided informed consent prior to
taking part in the study.
The protocol for this trial and supporting CONSORT checklist
are available as supporting information; see Checklist S1 and
Protocol S1.
For this study a team of naturopathic doctors at the Canadian
College of Naturopathic Medicine and its associated teaching
clinic (the Robert Schad Naturopathic Clinic) in Toronto, Canada
provided expert advice in designing a typical (but not necessarily
superlative) naturopathic intervention for anxiety symptoms. The
psychotherapy intervention was chosen based on previous studies
demonstrating its effectiveness[37], as well as the similarities in
patient-practitioner relationship and patient education to a
naturopathic intervention.
The study took place from March to July 2006 at two locations
of the Canada Post Corporation (CPC) in Ontario, Canada.
Canada Post employees who are members of the Canadian Union
of Postal Workers (CUPW) were recruited through poster
advertising. Interested employees received an information package
that included a sample informed consent form, background
information explaining the purpose of the study, a description of
the intended care as per study protocol, a question and answer
sheet regarding study participation, and contact information for
study enrolment. Participants came from a range of occupations
including mail carriers, transport drivers, and mail processors.
Baseline characteristics of the participants are discussed below and
summarized in Table 1.
All potential study participants were required to provide written
informed consent and to undergo a 1-hour assessment with a
naturopathic doctor (ND) including a non-structured psychiatric
interview according to DSM-IV criteria. Self-assessed anxiety
levels were quantified using the Beck Anxiety Inventory (BAI)
following this interview, and participants were centrally random-
ized to treatment or control group following collection of this data.
Participants’ BAI score was utilized to screen for those who
exhibited ‘moderate’ or ‘greater’ anxiety. In addition, the Beck
Depression Inventory (BDI) was used to screen participants for
conjoint depression as per exclusion criteria [38]. These self-report
questionnaires were selected as outcome measures to remain
consistent with the pragmatic nature of the study’s design. All
baseline outcome measures were collected at this time including
secondary outcome questionnaires, seated blood pressure, and
weight. Participants were given a dietary log to fill out that
included details on food, alcohol, caffeine, and cigarette
consumption as well as medication use. No participants were
currently undergoing adjunctive psychotherapy or other counsel-
ing for the treatment of their anxiety. Data on absenteeism and
expenditures on the employee health benefits plan were obtained
from the employer from participants who signed an additional
informed consent for the researchers to access this information for
a cost-benefit analysis as done in previous studies in this
occupational setting[39].
Participants were excluded if they could not comply with the
study protocol, had mild or no anxiety at the time of assessment
(BAI score,10), suffered from concomitant mild to severe
depression (BDI score.10), were currently taking prescription
medication that required daily doses of benzodiazepine class
drugs, had previously identified allergies or sensitivity to with-
anolides or Withania somnifera, abused substances such as alcohol or
illegal drugs, or had a severe concurrent illness. Participants were
also excluded if they were pregnant or breastfeeding. Use of
periodic or ad lib anxiety medications was monitored, but was not
a reason for exclusion.
Two licensed naturopathic doctors conducted enrollment and
provided on site delivery of care (OS, KC). This study was a
randomized pragmatic control trial comparing naturopathic care
to standard first-line treatment for anxiety (psychotherapy). The
treatment interventions were planned for 12 weeks. After
participants were considered eligible and baseline information
collected, they were randomized using age and gender matched
stratification to either naturopathic care (active group) (NC) or
psychotherapy (control group)(PT) from one of the two practi-
tioners (OS, KC) by an independent third party (DS) using a
computer generated randomization sequence. Assignment to
practitioner was based on chronology and by alternating back
and forth between the practitioners at the time of enrollment (i.e.
prior to any mutual knowledge or relationship of the patient and
practitioner). Allocation concealment using central randomization
was preserved up to the point of treatment. Although the analysts
and participants were blinded to treatment allocation, and
supplements were delivered using opaque, matched pills for all
the supplements and placebo used, it was not possible to mask the
interventions from the participants or the clinicians delivering
care. Care was taken in the informed consent to ensure that
Table 1. Baseline participant characteristics.
Parameter Naturopathic Care (NC) Psychotherapy (PT) P value
Gender 26 Female:15 Male 25 Female:15 Male 0.93
Age 52.02610.95 51.2868.18 0.73
BMI 28.2563.70 29.0265.08 0.43
Number of people using anxiety medication 6 7 0.73
BAI score 23.54610.13 23.45611.82 0.97
Number of current smokers 11 8 0.24
Caffeine doses/wk
* 11.78 15.91 0.209
*Caffeine doses were calculated based on reported consumption level of caffeinated drinks; 7 oz.Coffee=1.0; 1 serving cola=1, tea=0.5.
Values are shown6Std Deviation.
doi:10.1371/journal.pone.0006628.t001
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biases as equal as possible in both treatment groups.
Treatment Groups
Naturopathic care (NC). Participants receiving
naturopathic care were seen once per week for 30 minutes to
receive specific treatment for anxiety over a period of 12 weeks. A
licensed naturopathic doctor with more than 4 years of experience
administered the treatments during these sessions. During the
treatment sessions, data on patients’ lifestyle and diet was
obtained, and diaphragmatic deep breathing exercises were
performed. Lifestyle and nutritional counseling specific to the
individual patient was given with special emphasis on reducing
intake of stimulants (caffeine, cigarettes, chocolate), eating small,
meals at regular intervals, and increasing consumption of fruit,
fish, vegetables, nuts, and whole grains. Participants were
encouraged to exercise on a regular basis. Two supplements
were provided for participants to take throughout the trial: 1) the
herb Withania somnifera (Swiss - Ashwagandha) (standardized to
1.5% withanolides) taken at 300 mg, two times each day, and 2) an
adult multivitamin (Swiss - Senior Multi One) containing generic
vitamin and mineral components approved by the Natural Health
Products Directorate as a factor in the maintenance of good
health. Supplements were administered to the participants, and
compliance was assessed through pill count in 30-day increments
for the duration of the trial. All supplements and corresponding
placebo pills were manufactured and provided by Swiss Herbals
using certified Good Manufacturing Practices.
Although individualized treatment of patients is a highly
emphasized tenet that governs the practice of naturopathic
medicine, this ‘generalized’ treatment protocol was designed by
a group of experienced naturopathic doctors at a naturopathic
educational institution for the purposes of this trial. Consideration
was given to the overall concerns and typical needs of this
population of participants in drafting the naturopathic treatment
protocol, including the need to address generalized anxiety,
physical and mental strain, improper sleeping schedules, a holistic
view of health, overuse of stimulating substances, and support
optimal health within the context of the workplace. Characteristics
of the Canada Post population as well as the experiences of two
naturopathic doctors (OS, KC) involved in a previous trial
provided the basis for the study intervention [40]. Overall,
treatments for the naturopathic group contained an element of
individualized counseling, therapeutic doctor-patient relationship,
patient education, a mind-body exercise, patient motivation, and a
‘pill’. Treatments involving individualized recommendations were
made at the discretion of the investigator providing study care.
Psychotherapy (PT). Participants randomized to this control
group received psychotherapy consisting of patient directed
counseling and cognitive behavioural therapy for 30 minutes
each week for 12 weeks for anxiety as well as matched placebo
pills. During these sessions, participants received cognitive
restructuring exercises for the symptoms of anxiety delivered by
a practitioner with 5 years of training and experience in cognitive
behavioural therapy. In addition, participants were educated on
the importance of maintaining a healthy diet, reducing stimulants
(caffeine and tobacco), and taught a deep breathing exercise at the
start of the trial. In an effort to provide effective control measures,
participants in this group were asked about their dietary habits and
stimulant use throughout the trial with no continued dietary or
lifestyle counseling. Essentially, this meant that participants were
made aware of the importance of these issues without ongoing
advice. Participants were encouraged to exercise. Opaque,
matched placebo pills (2 pills, taken twice daily) consisting of an
inert fiber substance were administered and participant
compliance was assessed identically to that of the naturopathic
group. Careful consideration was given in the design of the
treatments to provide an effective treatment for anxiety while
creating an adequately matched ‘placebo’ to the active group As
such, the control group treatments contained an element of
individualized counseling, therapeutic doctor-patient relationship,
patient education, a mind-body exercise, patient motivation and a
‘pill’. Treatments involving individualized recommendations were
made at the discretion of the investigator providing study care.
Outcomes
Primary Outcome. The primary outcome for this study was
the Beck Anxiety Inventory (BAI). This questionnaire is designed to
measure subjective symptoms of anxiety, as well as discriminate
between anxiety and depression. The BAI consists of 21 items,
each describing a common symptom of anxiety. The items are
summed to obtain a total score that can range from 0–63. The
scale has high internal consistency and validity [41].
Secondary Outcomes
Secondary outcome measures included three questionnaires
related to quality of life administered at 4, 8 and 12-week time
points:
1. The short form –36 (SF-36) questionnaire is a self-administered,
36-item questionnaire that measures health-related quality of
life in eight domains: physical functioning, limitations due to
physical problems, limitations due to emotional problems,
vitality, measuring perceived level of energy and fatigue,
freedom from bodily pain, social functioning, mental health,
emotional state, and general health perceptions. Both physical
and mental summary scores can be obtained. Each domain is
scored separately from 0 (worst score) to 100 (best score). Two
summary scores can be calculated from information obtained
in the 8 domains- Physical Function and Mental Health
Summary Scores [42].
2. The Fatigue Questionnaire (FQ) is a 21-item instrument developed
for use in population studies to measure physical and mental
aspects of fatigue, a feature commonly observed in many
somatizing patients with anxiety. Each item has 7 response
options, with lower scores corresponding to high levels of
fatigue [43].
3. Measure Yourself Medical Outcomes Profile (MYMOP) is a patient-
centered outcome questionnaire with internal consistency and
construct validity [44,45,46]. It has been used extensively in
primary care and complementary medicine settings as a means
of garnering and quantifying qualitative patient experiences.
Patients choose two personally relevant symptoms of greatest
importance to their individual health and rate these symptoms
on a 7-point visual analogue scale. Higher scores correspond to
a lower satisfaction (i.e. worse) level of health as it pertains to
individually selected symptoms.
In addition, a series of 7-point visual analogue scale (VAS)
questions were administered at 4, 8, and 12-week time points to
measure participants subjective impressions of their own: compli-
ance to the treatment protocol; benefit from the treatment; how
well the study treatments met their expectations for treating their
anxiety; interest in pursuing treatments; and ability to cope with
stress since starting study treatments. Higher scores on the VAS
corresponded to greater positive subjective impression in the
individual parameter. Although the study was not powered to
measure significance in these VAS measures, it was expected that
Naturopathic Care for Anxiety
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variance in the non-specific effects between active and control
group. We hypothesized that minimal inter-group differences in
these parameters would correspond to a high correlation in non-
specific effects between the two groups; essentially well-matched
comparator treatments [47].
Statistical analysis
All analyses were performed by a statistician (QZ) under blinded
conditions using SAS/STAT (Version 9.1, Cary, NC). The data at
baseline visit and week 12 visit were summarized by mean and
standard deviation. When the missing data occurred at week 12,
its value was replaced by the value at week 8 as part of intention to
treat analysis. For each group, the treatment effect at week 12 was
compared to the baseline and assessed by the paired t-test. The
mean difference, its 95% confidence interval and p-value were
reported. The difference of the treatment effect between the NC
group and the PT group was compared by the independent t-test.
The mean difference of the treatment effect, its 95% confidence
interval and p-value are reported. The decision to not conduct a
sensitivity analysis between per-protocol and intention to treat was
made prior to the conduct of the study and then re-evaluated post
hoc. This decision was based on the low number of dropouts prior
to week 8 and minimal adverse reactions expected.
Sample size
In order to determine a 20% reduction in anxiety scores, and
assuming a population standard deviation of 20%, we calculated a
sample size of 37 was necessary in each arm, providing 80% power
at a 5% alpha value [48]. To supplement expected loss-to-follow-
up, we were committed to enrolling at least 80 participants (at least
40 in each arm).
All patients with available data were analyzed according to the
arm to which they were randomized using intention-to-treat. We
summarized the baseline data and the data at week 12 by mean
and standard deviation. For any missing data at week 12, we
carried forward the value at week 8. The means over the 12-week
period were plotted for the outcomes of BAI, SF-36, and FQ
component separately. To assess the treatment effect for each
group we calculated the mean change in scores between groups at
week 12 and the baseline. We also calculated the mean changes
between groups to examine the group effect. The statistical
significance of the changes for each group were tested using the
paired t-test; the exact 2-sided p-value is reported. To compare the
change scores between groups, the two-sample t-test was
performed. All p-values are 2-sided. Statistical analyses were done
with the SAS (version 9.1) software package.
Outcomes reported from these analyses include: FQ dimension
score, weight and BMI (Table 2); BAI and perceived benefit
questionnaire (Table 3); SF-36 (Table 4) and adverse reactions
(Table 5).
Results
Recruitment and Follow-up of Patients
Figure 1 describes the flow of participants through the trial. 119
people were screened, with 87 meeting inclusion/exclusion
criteria. Of the 32 excluded participants, 16 had zero to mild
anxiety (BAI,10), 4 had mild to severe conjoint depression
(BDI.10), 2 were consuming daily doses of prescription
benzodiazepine medication for treatment of their anxiety, and
10 could not commit to the time required to take part in the trial.
Patients that were identified as having mild to severe depression
were referred for appropriate treatment. Age and gender based
central randomization occurred for the remaining 87. OS
provided study care to 43 participants; KC provided study care
to 44 participants. Six of the 87 participants withdrew from the
study before starting treatment; three of whom had been
randomized to the active treatment group and three randomized
to the control group. Four of the six cited time constraints as a
reason for withdrawal, and two participants had major changes in
their health status and were advised not to participate in the study
on the advice of their family physician. Baseline analysis was
conducted with the remaining 81 participants that began
treatment. During the course of the study, eight patients withdrew
from the NC group, and nine withdrew from the PT group. A total
of nine patients withdrew due to time constraints, six patients were
lost on follow-up with no discernable reason cited for withdrawal,
two patients (both from PT group) withdrew on the advice of their
Table 2. Fatigue questionnaire, Weight and BMI results.
Outcomes Group
Baseline
Mean6Std (N)
Week 12
*
Mean6Std (N)
Change at 12 wks from baseline
Mean (95%CI) (N, p-value)
Difference of changes between
groups Mean (95%CI) P-value
FQ Subjective NC 66.55617.96 (41) 47.17620.52 (36) 220.39 (226.41, 214.37) (36, ,0.0001) 218.01(225.16, 210.85) ,0.0001
PT 65.98615.79 (40) 63.23615.01 (39) 22.38 (26.63, 1.87) (39, 0.2634)
FQ physical NC 52.03621.96 (41) 38.89618.69 (36) 214.29 (220.63, 27.95) (36, ,0.0001) 213.19 (221.85, 24.52) 0.0033
PT 55.12623.08 (40) 53.60617.23 (39) 21.10 (27.22, 5.02) (39, 0.7182)
FQ Motivation NC 56.79619.82 (41) 39.48616.49 (36) 218.95 (226.30, 211.60) (36, ,0.0001) 220.32 (229.05, 211.59) ,0.0001
PT 52.23617.09 (40) 53.57613.56 (39) 1.37 (23.81, 6.56) (39, 0.5946)
FQ Concentration NC 61.74617.37 (41) 45.24619.34 (36) 217.14 (223.75, 210.54) (36, ,0.0001) 217.51 (225.89, 29.13) ,0.0001
PT 56.00617.93 (40) 55.82620.44 (39) 0.37 (25.10, 5.83) (39, 0.8928)
Weight NC 76.60613.16 (41) 74.76612.22 (36) 21.98 (22.85, 21.11) (36, ,0.0001) 21.47 (22.64, 20.30) 0.0146
PT 81.13618.96 (40) 80.42619.06 (39) 20.51 (21.32, 0.30) (39, 0.2089)
BMI NC 28.2563.70 (41) 27.5363.14 (36) 20.75 (21.08, 20.42) (36, ,0.0001) 20.56 (21.00, 20.12) 0.0128
PT 29.0265.08 (40) 28.8065.08 (39) 20.19 (20.49, 20.11) (39, 0.2136)
Week 12
* - the week 8 value was used for week 12 if the week 12 data was missing.
NC=Naturopathic Care; PT=Psychotherapy.
doi:10.1371/journal.pone.0006628.t002
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Outcomes Group
Baseline
Mean6Std (N)
Week 12
*
Mean6Std (N)
Change at 12 wks from baseline
Mean (95%CI) (N, p-value)
Difference of changes between
groups Mean (95%CI) P-value
BAI total score NC 23.54610.13 (41) 10.89611.69 (36) 213.31(216.51, 210.12) (36, ,0.0001) 26.16 (210.24, 22.08)0.0036
PT 23.45611.82 (40) 16.28610.89 (39) 27.15 (29.84, 24.47) (39, ,0.0001)
MY-MOP Symptom 1 NC 5.2061.25 (41) 2.8861.25 (36) 22.24 (22.75, 21.72) (36, ,0.0001) 21.77 (22.59, 20.95) ,0.0001
PT 4.4361.45 (40) 3.9761.53 (39) 20.46 (21.10, 0.17) (39, 0.1492)
MY-MOP Symptom 2 NC 4.7861.23 (40) 2.79061.49 (34) 21.94 (22.43, 21.45) (34, ,0.0001) 21.08 (21.90, 20.25) 0.0115
PT 4.8461.69 (38) 3.8761.36 (38) 20.86 (21.53, 20.20) (37, 0.0126)
Compliance (VAS measure)
** NC 4.7961.51 (40) 5.2960.94 (36) 0.66 (0.30, 1.01) (35, 0.0006) 0.28 (20.16, 0.71) 0.2071
PT 4.9261.24 (39) 5.3761.16 (39) 0.38 (0.11, 0.65) (38, 0.0066)
Benefit
** NC 4.7061.80 (40) 5.7960.92 (36) 1.24 (0.67, 1.82) (35, 0.0001) 1.14 (0.46, 1.82) 0.0014
PT 4.5861.47 (40) 4.7461.23 (39) 0.10 (20.31, 0.51) (39, 0.6164)
Interest
** NC 5.6061.44 (39) 5.7661.24 (36) 0.264 (20.23, 0.76) (34, 0.2870) 0.008 (20.64, 0.65) 0.9795
PT 5.0861.59 (40) 5.2861.23 (39) 0.256 (20.17, 0.69) (39, 0.2351)
Expectation
** NC 4.8061.59 (40) 5.5761.09 (36) 1.01 (0.49, 1.54) (35, 0.0004) 0.73 (0.08, 1.38) 0.0272
PT 4.5561.32 (40) 4.7761.17 (39) 0.28 (20.13, 0.69) (39, 0.1722)
Stress
** NC 5.0061.26 (40) 5.8360.85 (36) 0.91 (0.48, 1.35) (35, 0.0001) 0.81 (0.24, 1.37) 0.0055
PT 4.4161.23 (39) 4.4561.11 (38) 0.10 (20.27, 0.49) (37, 0.5646)
Week 12
* - the week 8 value will be used for week 12 If missing value is occurred at week 12.
**- week 4 was considered baseline for these outcome measures.
NC=Naturopathic Care; PT=Psychotherapy.
doi:10.1371/journal.pone.0006628.t003
Table 4. SF-36 results.
Outcomes SF-36 Group
Baseline
Mean6Std (N)
Week 12
*
Mean6Std (N)
Change at 12 wks from baseline
Mean (95%CI) (N, p-value)
Difference of changes between
groups Mean (95% CI) P-value
Aggregate physical
component
NC 46.2367.99 (36) 49.8367.24 (34) 3.76 (1.28, 6.23) (32, 0.0042) 3.26 (20.15, 6.66) 0.0608
PT 45.5168.82 (39) 46.5967.98 (38) 0.50(21.91, 2.91) (37, 0.6768)
Aggregate mental
component
NC 38.9769.81 (36) 50.9267.29 (34) 12.56 (9.02, 16.10) (32, ,0.0001) 10.34 (5.21, 15.46) 0.0001
PT 39.0369.95 (39) 41.54610.61 (38) 2.23 (21.54, 5.99) (37, 0.2378)
Physical functioning NC 44.15610.95 (41) 50.4368.73 (36) 5.61 (3.10, 8.13) (36, ,0.0001) 4.88 (0.99, 8.76) 0.0145
PT 44.69611.19 (40) 46.02611.44 (39) 0.73 (22.27, 3.74) (39, 0.6334)
Role physical NC 44.9967.88 (39) 48.6268.41 (36) 4.34(1.61, 7.07) (35,0.0028) (20.11, 7.78) 0.0564
PT 44.1869.49 (40) 44.8668.92 (39) 0.50 (22.40, 3.41) (39, 0.7181)
Bodily pain NC 40.5568.63 (39) 48.0467.93 (35) 7.77 (5.30, 10.24) (41, ,0.0001) 4.40 (0.96, 7.85) 0.0130
PT 41.0769.66 (40) 45.0668.41 (38) 3.36 (0.89, 5.84) (40, 0.0091)
General health NC 43.0369.95 (40) 49.9169.38 (35) 6.70 (3.74, 9.65) (35, ,0.0001) 7.13 (3.34, 10.92) 0.0004
PT 43.7768.74 (40) 43.4967.13 (39) 20.43 (22.95, 2.08) (39, 0.7286)
Vitality NC 42.5069.88 (41) 53.31610.08 (36) 11.27 (7.46,15.09) (36, ,0.0001) 9.43 (4.77, 14.09) 0.0001
PT 42.1068.37 (40) 44.1768.65 (39) 1.84 (21.05, 4.73) (39, 0.2046)
Social functioning NC 37.90611.32 (40) 48.1267.85 (35) 10.27 (6.06, 14.48) (34, ,0.0001) 7.40 (2.07, 12.72) 0.0072
PT 38.95611.19 (39) 42.3169.64 (39) 2.87 (20.61, 6.35) (38, 0.1031)
Role emotional NC 39.6568.48 (40) 48.5468.80 (36) 9.22 (5.40, 13.04) (35, ,0.0001) 7.42 (1.86, 12.99) 0.0096
PT 40.33610.64 (40) 42.32613.13 (39) 1.79 (22.32, 5.91) (39, 0.3833)
Mental health NC 40.22610.75 (40) 48.83611.03 (36) 9.49 (5.63, 13.36) (35, ,0.0001) 6.84 (1.69, 12.10) 0.0102
PT 40.7969.06 (40) 43.6569.55 (39) 2.60 (21.03, 6.23) (39, 0.1553)
Week 12
* - the value at week 8 was used for week 12 If the missing value was occurred.
NC=Naturopathic Care; PT=Psychotherapy.
doi:10.1371/journal.pone.0006628.t004
Naturopathic Care for Anxiety
PLoS ONE | www.plosone.org 6 August 2009 | Volume 4 | Issue 8 | e6628medical doctor and one patient was required to withdraw due to a
positive pregnancy test.
Baseline characteristics
Randomization was stratified based on age and gender. Both
treatment groups had similar characteristics including baseline
BAI score, number of users of prescription anxiety medication,
and use of stimulants (number of smokers, use of caffeine). Table 1
provides a summary of baseline characteristics.
Study treatments
Study treatments were well received, as shown by expectation
scores demonstrated by the VAS and good compliance rates in
both groups. The mean total of missed supplements was 6.83 pills
Table 5. Adverse reactions.
Type NC PT
Gastrointestinal upset 2 2
Overstimulation 2 2
Rash 0 1
‘Feeling warm’ 1 0
Increased frequency of nocturnal night cramps 1 1
Mild hair loss 1 1
NC=Naturopathic Care; PT=Psychotherapy.
doi:10.1371/journal.pone.0006628.t005
Figure 1. Flowchart of participants through trial.
doi:10.1371/journal.pone.0006628.g001
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throughout the 12-week duration of the trial.
Outcomes
Significant improvements from baseline on the primary
outcomes measure (BAI) were seen in both the naturopathic
(213.31; p-value,0.0001) and psychotherapy (27.15; p-val-
ue,0.0001) groups (see Table 3). There was significantly greater
improvement in the BAI in the naturopathic treatment group as
opposed to the psychotherapy group (p=0.003) (Fig. 2). Statisti-
cally significant differences as well as trends for differences were
observed between groups in FQ subscales; subjective fatigue
(p,0.0001), physical fatigue (p=0.003), motivation (p,0.001),
and concentration (p=,0.0001) with NC group showing greater
improvement as compared to PT (Table 2). Patient centered
outcomes as measured by the MYMOP questionnaire showed
significant reductions in symptoms 1 (p,0.0001) (Fig. 3) and
symptom 2 (p=0.012) (Fig. 4) in the NC group as compared to the
PT group (Table 3). Other statistically significant differences
occurred in SF-36 aggregate mental component (p,0.0001),
General Health (p=0.0004), Vitality (p,0.0001), Social Func-
tioning (p=0.007), Role Emotional (0.0096) and Mental Health
(p=0.010) subscales as well as on mental (p,0.0001) aggregate
scores (Table 4). A non-significant trend between group improve-
ments was observed in aggregate physical component (p=0.061),
and Role Physical (p=0.056) and Bodily Pain (p=0.013)
subscales.
Adverse Events
Table 5 summarizes the frequency of all adverse reactions
observed and/or reported according to treatment group. No
differences were observed between groups; gastrointestinal upset
and feeling of ‘overstimulation’ were the most commonly reported
in both groups. Gastrointestinal complaints consisted of incidence
of nausea or stomach pain lasting 1–2 hours after taking the pills.
Complaints of ‘overstimulation’ (participant’s word) include
feelings of increased mental and, or physical agitation lasting 4–
6 hours. All reported reactions were considered to be mild by
participants reporting them.
Costs effectiveness
22 (25%) of participants were willing to give consent for the
researchers to access absenteeism and data on health care
expenditures under the employee health benefits insurance
program. A sample size this small proved to be unsuitable for
cost-effectiveness analysis and is a limitation of the research study.
This limitation based on participation may, in part, be due to
increased apprehension surrounding issues of informed consent
and researcher access to this information in the study’s population.
Discussion
Our results should be of interest to patients, clinicians and
workplace-related health services alike. Results of this study
indicate a significant reduction in anxiety level from the use of
either naturopathic care or a standardized psychotherapy
intervention in this workplace setting. These results are consistent
with systematic reviews on the short-term efficacy of counseling in
the treatment of anxiety [49]. Further research studies on the
effects of either of these interventions in other workplace settings
are warranted, particularly with respect to impact on worker
presenteeism and cost-effectiveness based on larger-scale imple-
mentation. Comparatively, naturopathic treatment showed a
clinically and statistically significant improvement in anxiety and
quality of life measures as compared to the control standard.
Our study demonstrates that naturopathic treatments, cognitive
behavioral therapy and counseling have a significant effect on
decreasing the symptoms of anxiety. In addition, naturopathic
treatments including dietary changes and the herb Withania
somnifera have additional secondary effects on quality of life of
individuals in the workplace, including significant reduction in
stress and improved vitality, motivation, general health, and
patient-specific concerns. Few participants in the study were
receiving treatment for anxiety despite remarkable symptoms of
anxiety and dysfunctional mental health. This observation is
consistent with the persisting stigma surrounding mental health
Figure 2. Beck Anxiety Inventory results.
doi:10.1371/journal.pone.0006628.g002
Figure 3. MYMOP – Symptom 1 results.
doi:10.1371/journal.pone.0006628.g003
Figure 4. MYMOP – Symptom 2 results.
doi:10.1371/journal.pone.0006628.g004
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from this pragmatic study on providing access to care and ongoing
treatment for all the participants were notable and highly valued
by the workplace.
Limitations
This was a pragmatic randomized controlled trial, and as such,
it is difficult to ascertain the precise effect of each of the
component therapies of the NC and PT treatment packages.
Future research trials employing a multi-factorial design would
assist in isolating and characterizing the effects of single and
combination treatments.
Maintaining internal and external validity in pragmatic RCTs is
a challenge [51,52]. Our study design attempted to maximize
external validity (generalizability) by having few exclusion criteria
and including some flexibility or variability in study interventions
based on individual needs (e.g. specific advice given in counseling or
dietary advice). However, one specific herbal component was used
to treat all study participants in the NC group despite the range of
potential psychoactive herbs with varying degrees of supportive
evidence [53]. Treatment decisions made by the naturopathic
doctors in the study was limited as a result, thus decreasing the
external validity of our study. The overall generalizability of our
results is limited, in part, due to small sample size.
Internal validity was achieved by: attempting to account for
non-specific effects of treatments in both groups; absence of
assessment bias; and preventing contamination [51,52]. Both the
NC and PT groups received: individualized counseling, therapeu-
tic doctor-patient relationship, patient education, a mind-body
exercise, patient motivation, and a ‘pill’. In addition, both
treatment groups reported that their expectations for treatment
were being effectively met on 7-point VAS throughout the course
of the study (NC: 5.57, PT: 4.77). Assessment and data analysis
was conducted blind to group allocation. No contamination of the
PT group with respect to Withania use or visits to a naturopathic
doctor occurred. No patients in either group were undergoing
active counseling or psychotherapy outside this study. Lack of a
‘no treatment’ control group limits the internal validity of this
study; we are unable to account for spontaneous changes in
anxiety levels or regression to the mean within the study design.
However, the natural course and severity of anxiety is generally
consistent over time when it has been present with a large degree
of chronicity (.6 months)[2].
Although a statistically significant difference in reduction of
anxiety symptoms was observed between NC and PT treatment,
we observed some methodological challenges based on our study
population and study design. Sample size calculation was based on
detecting a clinically and statistically significant effect size (620%)
on BAI scores from baseline, however both the NC and PT groups
demonstrated significant reductions in BAI scores (NC 56.5%, PT
30.5%) thus minimizing the ability to detect the differential effect
size [54]. In addition, the heterogeneity of the study participants,
as reflected by the large variability in BAI scores, impacts
negatively on predictability and the ability to detect between
group differences [54].
Additionally, it should be highlighted that this study investigated
changes in patient-reported symptoms of anxiety. Future studies
would need to employ the use of blinded independent assessment
of this disorder using a structured diagnostic interview based on
DMS-IV criteria (SCID) throughout the study to gather non-
patient rated information relating to anxiety.
Conclusion
Naturopathic treatment including Withania somnifera, a multi
vitamin, dietary counseling and cognitive-behavioral therapy
appears to be a safe and effective, with benefit over standardized
psychotherapy in the treatment of mild to severe generalized
anxiety in the Canada Post worker population. Future research is
required to examine effects of the individual components of
treatments as well as the nature of the therapeutic relationship in
mental health disorders like anxiety.
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